BRAF V600E–Targeted Therapy Combined with PD-1 Blockade in Anaplastic Thyroid Carcinoma: Mechanistic Rationale, Emerging Clinical Evidence, and Resistance Biology

Introduction

Anaplastic thyroid carcinoma (ATC) is among the most aggressive human malignancies, historically associated with a median overall survival (OS) of less than six months. The identification of BRAF V600E as a druggable driver alteration—present in approximately 25–45% of ATC tumors—catalyzed a therapeutic revolution centered on combined BRAF and MEK inhibition with dabrafenib and trametinib (D+T). Yet even with robust initial responses, acquired resistance and relapse remain formidable challenges. Layering immune checkpoint blockade targeting programmed death-1 (PD-1) onto this MAPK (mitogen-activated protein kinase)–targeted backbone has emerged as a compelling strategy to deepen and prolong disease control. This review synthesizes the mechanistic rationale, established clinical evidence for D+T monotherapy, emerging triplet-therapy data, resistance biology, and future directions—distinguishing established findings from hypothesis-generating evidence throughout.

Mechanistic Rationale for Combining BRAF/MEK Inhibition with PD-1 Blockade

The scientific rationale for coupling MAPK pathway inhibition with PD-1 blockade rests on three converging mechanisms 12317.

First, BRAF V600E–driven MAPK signaling actively suppresses tumor immunogenicity: it downregulates antigen-processing machinery, impairs MHC class I expression, and promotes an immunosuppressive tumor microenvironment (TME) enriched in tolerogenic cytokines. Targeted suppression of this pathway with dabrafenib and trametinib can reverse these effects—upregulating antigen presentation, enhancing interferon signaling, and increasing CD8+ T-cell infiltration into the tumor stroma, effectively converting an immunologically "cold" TME into a more inflamed and T-cell–accessible state 1917.

Second, MEK inhibition has been shown, in preclinical models, to reduce downstream pERK signaling in a manner that can modulate T-cell cytokine programs without abolishing CD4+/CD8+ T-cell function, while simultaneously inducing tumor-cell apoptosis and upregulating immunogenic surface markers 12. SHP2 blockade in ATC models further reinforces this concept, demonstrating increased dendritic cell phagocytosis, greater CD8+ T-cell infiltration, and a proinflammatory cytokine milieu following MAPK pathway perturbation 9.

Third, MAPK pathway inhibition and/or the development of resistance to BRAF inhibition can paradoxically upregulate PD-L1 expression on tumor cells, providing a mechanistic cue for adding PD-1/PD-L1 blockade to sustain anti-tumor immunity 1. Preclinical melanoma models demonstrated that concurrent or MAPK inhibitor–led sequencing to PD-1 blockade yields superior tumor control and T-cell infiltration compared with anti–PD-1–first strategies 1. PD-L1 positivity in ATC has been correlated with shorter progression-free survival in retrospective analyses, further supporting the biologic relevance of this axis in ATC 4. For BRAF class 3 mutants (e.g., D594N) co-occurring with NRAS alterations—where oncogenic signaling is CRAF- and RAS-dependent—combined BRAF/MEK inhibition can suppress this cross-talk while PD-1 blockade sustains T-cell activity, potentially converting immunotherapy-resistant ATC into a more immunoreactive tumor 11.

Established Clinical Evidence: Dabrafenib plus Trametinib Monotherapy in BRAF V600E–Mutant ATC

The pivotal evidence for D+T in BRAF V600E–mutant ATC derives from the phase II, open-label ROAR basket trial. While the initial interim analysis included a smaller response-evaluable cohort, the updated analysis reported outcomes for 36 patients with BRAF V600E–mutant ATC 518. Patients received dabrafenib 150 mg twice daily plus trametinib 2 mg once daily. In the initial interim analysis, the confirmed ORR was 69% (11/16). In the subsequently updated ROAR analysis including 36 patients, ORR was 56%, median PFS was 6.7 months, median OS was 14.5 months, and the 12-month OS rate was 51.7%—though medians were not reached given limited events and the small cohort size 5. The safety profile was manageable: fatigue (38%), pyrexia (37%), and nausea (35%) were the most common adverse events; grade 3/4 events included hyponatremia (19%), pneumonia (13%), and anemia (13%) 5. Italian real-world data from eight centers (n=19) corroborated these activity signals in routine clinical practice, with a median OS of approximately 21 months in this heavily pretreated population 14. Guidelines from the NCCN (2025) and the FAST (MD Anderson–affiliated) expert consensus recognize D+T as a cornerstone targeted option in BRAF V600E–mutant ATC, including in neoadjuvant settings for select resectable cases, and emphasize rapid molecular testing to enable timely therapeutic deployment 67.

Emerging Clinical Data: Adding PD-1 Blockade to BRAF/MEK Inhibition

The most substantive emerging signal for triplet therapy comes from a multicenter US neoadjuvant study (reflected in ASCO 2025 data and the ongoing prospective trial NCT04675710), evaluating neoadjuvant pembrolizumab added to D+T (DTP) in BRAF V600E–mutant ATC 1215. Among 36 evaluable patients, radiographic responses (partial response or complete response) occurred in 72%; 30 patients proceeded to surgical resection, of whom 97% achieved R0 or R1 margins—a remarkable downstaging signal in a disease rarely amenable to complete resection. Pathologic complete response was documented in 20/30 (67%) of resected specimens. With a median follow-up of approximately 18 months, median OS approached 20 months, 1-year OS was 71%, and 2-year OS 48%; median PFS was 13.9 months 12. Grade 5 adverse events occurred in approximately 22% of patients, a figure requiring careful contextual interpretation given the natural history of ATC, though no deaths were definitively attributed to treatment; immune-related adverse events (irAEs) including hepatitis and colitis were observed 12. These results are compelling but must be interpreted in light of the single-arm, nonrandomized design, potential selection bias toward patients eligible for curative-intent surgery, and the absence of a D+T comparator arm.

Retrospective multi-institutional data (published in Thyroid, 2024) provide additional, albeit hypothesis-generating, support 13. Among 71 patients with BRAF V600E–mutant ATC receiving DT with or without PD-1 blockade, those receiving concurrent pembrolizumab demonstrated longer median OS (approximately 17 vs. 9 months with DT alone) and longer median PFS (approximately 11 vs. 4 months). Immune-related adverse events affected approximately one-third of patients; no grade 5 toxicity attributable to treatment was reported. Critically, this study's retrospective design and potential confounding by patient selection, baseline characteristics, and treatment heterogeneity limit causal inference—the survival difference, while notable, requires prospective confirmation.

At the case-report level, a patient with ATC harboring NRAS Q61R and BRAF D594N mutations—and high PD-L1 expression (tumor proportion score 60%)—achieved a pathologic complete response following salvage dabrafenib, trametinib, and sintilimab (a PD-1 inhibitor) after prior progression on PD-1/anti-angiogenic combination 11. This single-case experience, though not generalizable, provides mechanistic and clinical proof-of-concept for triplet therapy in BRAF non-V600/RAS-co-mutant ATC.

Real-world data from Fudan University Shanghai Cancer Center (FUSCC), encompassing 95 PDTC (poorly differentiated thyroid carcinoma)/ATC patients treated from 2019 to 2023, demonstrated that in a BRAF V600E–enriched subset, neoadjuvant therapy followed by surgery emerged as an independent predictor of superior OS in multivariate modeling (hazard ratio approximately 0.216), with 1-year OS of approximately 50–60% across subgroups 20. While heterogeneous and retrospective, these data reinforce the feasibility and potential benefit of integrating D+T and PD-1 inhibitors within neoadjuvant frameworks internationally.

Resistance Pathways and Relapse Biology

Resistance to MAPK-targeted therapy and immune checkpoint blockade in ATC likely involves multiple, overlapping mechanisms, including MAPK pathway reactivation, activation of parallel signaling pathways, and immune-evasion processes 817. Acquired resistance to BRAF/MEK inhibition can arise through MAPK pathway reactivation—including secondary BRAF amplification, alternative splice forms, upstream RAS mutations, or MEK1/2 mutations—or through activation of parallel pro-survival pathways, particularly PI3K/AKT/mTOR, which bypasses suppressed MAPK signaling. Tumor-intrinsic adaptation can also include epithelial-to-mesenchymal transition (EMT) and dedifferentiation, further reducing antigen presentation and immune recognition. Immunologically, resistance mechanisms encompass loss of MHC class I expression, enrichment of immunosuppressive cell populations (regulatory T cells, myeloid-derived suppressor cells), altered cytokine milieu, and changes in the broader TME that blunt PD-1 axis efficacy 8. In ATC, given the dynamic MAPK signaling landscape and typically high PD-L1 expression, simultaneous dampening of MAPK signaling and immune checkpoint inhibition may partially mitigate certain forms of intrinsic resistance, though ATC-specific prospective resistance data remain limited in the retrieved literature 8.

Clinical Implications and Future Directions

Several practical considerations emerge from this evidence synthesis. Patient selection must begin with validated BRAF V600E testing—reflex molecular profiling at diagnosis is strongly recommended, with comprehensive DNA/RNA next-generation sequencing (NGS) if BRAF is negative, to identify co-occurring alterations and actionable targets 16. Biomarker-informed stratification using PD-L1 expression, tumor mutational burden (TMB), and immune contexture (e.g., tertiary lymphoid structure features) will be critical to identifying patients most likely to benefit from triplet therapy and monitoring resistance emergence.

Sequencing versus concurrent combination requires prospective clarification. Preclinical data suggest that MAPK inhibitor–led or concurrent approaches may be preferable to immunotherapy-first strategies 1, but ATC-specific sequencing trial data are absent from the retrieved literature. The prospective NCT04675710 trial directly addresses whether preoperative DTP can improve surgical outcomes and long-term disease control, and its results are eagerly awaited 15.

Toxicity management is essential: pyrexia is a class hallmark of D+T; structured fever management algorithms (interrupting both agents at fever onset ≥38°C and restarting after ≥24 hours symptom-free) have reduced serious pyrexia-related outcomes in other D+T indications and should be applied proactively in ATC practice 10. The addition of PD-1 blockade introduces irAEs (hepatitis, colitis, pneumonitis), which were manageable but clinically meaningful in triplet cohorts. Multidisciplinary decision-making, including endocrinology, surgical oncology, and radiation oncology expertise, remains indispensable.

Looking ahead, next-generation strategies may incorporate SHP2 inhibition or PI3K/AKT/mTOR targeting alongside D+T and PD-1 blockade to forestall parallel resistance pathways 98. Prospective, controlled trials with integrated biomarker programs are urgently needed to move beyond the current landscape of small, nonrandomized, and retrospective data.

Evidence Summary Table

Conclusion

The combined application of dabrafenib, trametinib, and PD-1 blockade in BRAF V600E–mutant ATC represents one of the most promising therapeutic advances in a disease that has historically been uniformly lethal. D+T monotherapy is established as the cornerstone targeted regimen, with a phase II ORR of 69% and durable 12-month survival signals that were unprecedented in ATC 5. The mechanistic case for adding PD-1 blockade is scientifically compelling—rooted in MAPK-driven TME reprogramming, enhanced antigen presentation, and T-cell reinvigoration 12917—and is now buttressed by retrospective and early prospective data suggesting improved depth and duration of response with triplet therapy 1213. Nevertheless, the field must exercise appropriate rigor: the existing triplet evidence is nonrandomized, subject to selection bias, and far from definitive. Resistance mechanisms—MAPK reactivation, PI3K/AKT/mTOR bypass, and immune escape—will challenge even the most optimized combination approaches 8. Prospective, biomarker-integrated, randomized or controlled trials remain the critical next step to confirm the magnitude of benefit, define optimal sequencing, and refine patient selection for this evolving therapeutic paradigm.